Related Experiment Video
Updated: Dec 30, 2025
11:07
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
Published on: April 29, 2015
13.6K
Microfluidic-prepared DOTAP nanoparticles induce strong T-cell responses in mice
Yasunari Haseda1, Lisa Munakata2, Jie Meng1
1Vaccine Dynamics Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Plos One
|January 25, 2020
Summary
Microfluidic preparation of DOTAP nanoparticles, combined with D35, significantly enhances antigen-specific T-cell responses. This novel adjuvant formulation shows promise for therapeutic vaccines against cancer and infectious diseases.
Area of Science:
- Immunology
- Vaccinology
- Nanotechnology
Background:
- Inducing robust antigen-specific T-cell responses is crucial for effective vaccination.
- Vaccine adjuvants enhance immune responses by potentiating immune activity and facilitating antigen delivery.
- Cationic lipids like DOTAP are explored for their adjuvant properties.
Purpose of the Study:
- To investigate the efficacy of DOTAP-based nanoparticles as vaccine adjuvants.
- To compare microfluidic preparation with traditional liposomal formulation of DOTAP.
- To evaluate the impact of CpG D35 addition on T-cell induction.
Main Methods:
- Utilized microfluidics for the preparation of DOTAP nanoparticles.
- Formulated DOTAP nanoparticles with and without Type-A CpG D35.
- Assessed CD4+ and CD8+ T-cell responses induced by the adjuvant formulations.
- Investigated factors influencing adjuvant efficacy, including nanoparticle size and buffer conditions.
Main Results:
- Microfluidic preparation of DOTAP nanoparticles yielded stronger CD4+ and CD8+ T-cell responses compared to liposomal DOTAP.
- The addition of Type-A CpG D35 further augmented T-cell responses, particularly CD4+ T cells.
- Nanoparticle size, buffer conditions, and antigen interaction critically influence T-cell induction efficiency.
Conclusions:
- Microfluidic-prepared DOTAP nanoparticles represent a potent adjuvant platform.
- Combining DOTAP nanoparticles with D35 offers a promising strategy for enhancing therapeutic T-cell responses.
- This adjuvant system is suitable for vaccines targeting cancer and infectious diseases.
